LIVIVO - Search results -

Search results

Result 1 - 10 of total 15

Search options

Article ; Online: Efficacy and Safety of Edoxaban in Cancer-Associated Venous Thromboembolism: A Real World Retrospective Study.

Grifoni, Elisa / Baroncelli, Andrea / Pinto, Gabriele / Cosentino, Eleonora / Micheletti, Irene / Signorini, Ira / Panigada, Grazia / Landini, Giancarlo / Masotti, Luca

TH open : companion journal to thrombosis and haemostasis

2022 Volume 6, Issue 2, Page(s) e99–e106

Abstract: ... ...

Abstract	Introduction
Language	English
Publishing date	2022-03-01
Publishing country	Germany
Document type	Journal Article
ZDB-ID	2901738-5
ISSN	2512-9465 ; 2567-3459
ISSN (online)	2512-9465
ISSN	2567-3459
DOI	10.1055/a-1783-9744
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7138: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Efficacy and Safety of Edoxaban in Cancer-Associated Venous Thromboembolism: A Real World Retrospective Study

Grifoni, Elisa / Baroncelli, Andrea / Pinto, Gabriele / Cosentino, Eleonora / Micheletti, Irene / Signorini, Ira / Panigada, Grazia / Landini, Giancarlo / Masotti, Luca

TH Open

2022 Volume 06, Issue 02, Page(s) e99–e106

Abstract: Introduction: Few data exist on the use of edoxaban in cancer-associated venous thromboembolism (VTE) outside of clinical trials. Aim of this study was to evaluate the characteristics and outcomes of these patients in a real world clinical setting.: ... ...

Abstract	Introduction: Few data exist on the use of edoxaban in cancer-associated venous thromboembolism (VTE) outside of clinical trials. Aim of this study was to evaluate the characteristics and outcomes of these patients in a real world clinical setting. Methods: We retrospectively analyzed the characteristics of patients with cancer-associated VTE who were prescribed edoxaban. Follow-up at 3, 6, and 12 months was performed: VTE recurrences, bleedings, mortality, cancer progression and treatment, edoxaban interruption and its reason were assessed. Results: Fifty-four patients, 38 females (70.4%), mean age 71 ± 14 years, were enrolled. In 38 patients (70.4%), the episode of VTE was the first one, in 28 (51.8%) it was an isolated deep vein thrombosis (DVT), in 13 (24.1%) a pulmonary embolism (PE) associated with DVT, in 13 (24.1%) an isolated PE. Median time between cancer and VTE diagnosis was 6 (interquartile range [IQR] 2–47) months. Median time between VTE diagnosis and edoxaban prescription was 36 (IQR 7–117) days. At 3, 6, and 12 months the incidence of all-cause mortality was 16.6, 22.2, and 38.8%, that of VTE recurrence 1.8, 1.8, and 3.7%, and that of major bleeding 7.4, 9.2, and 12.9%, respectively. No bleeding was fatal. Of the 33 patients alive at 12 months, 32 (96.9%) were still on edoxaban therapy, in seven (21.2%) cancer was in progression. Conclusion: Our study, conducted on a real world population of patients with cancer-associated VTE, confirms the results of randomized controlled clinical trials, and supports the use of edoxaban as effective and safe treatment in this context.
Keywords	cancer ; venous thromboembolism ; bleeding ; edoxaban ; low molecular weight heparin
Language	English
Publishing date	2022-03-01
Publisher	Georg Thieme Verlag KG
Publishing place	Stuttgart ; New York
Document type	Article
ZDB-ID	2901738-5
ISSN	2512-9465 ; 2567-3459
ISSN (online)	2512-9465
ISSN	2567-3459
DOI	10.1055/a-1783-9744
Database	Thieme publisher's database

In stock of ZB MED Cologne/Königswinter

Zs.A 7138: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Direct Oral Anticoagulants in Patients Undergoing Urgent Reperfusion for Nonvalvular Atrial Fibrillation-Related Ischemic Stroke: A Brief Report on Literature Evidence.

Masotti, Luca / Grifoni, Elisa / Dei, Alessandro / Vannucchi, Vieri / Moroni, Federico / Panigada, Grazia / Nicotra, Costanza / Spolveri, Stefano / Landini, Giancarlo

Neurology research international

2019 Volume 2019, Page(s) 9657073

Abstract: Introduction: The optimal timing for starting anticoagulation in the early phase of nonvalvular atrial fibrillation (NVAF)-related acute ischemic stroke (AIS) remains a challenge, especially in patients undergoing urgent reperfusion by systemic ... ...

Abstract	Introduction: The optimal timing for starting anticoagulation in the early phase of nonvalvular atrial fibrillation (NVAF)-related acute ischemic stroke (AIS) remains a challenge, especially in patients undergoing urgent reperfusion by systemic thrombolysis or mechanical thrombectomy. The aim of our study was to review the literature evidence reporting on safety of direct oral anticoagulants (DOACs) starting in the early phase of NVAF-related AIS undergoing systemic thrombolysis and/or mechanical thrombectomy. Materials and methods: We reviewed the PubMed databases searching articles reporting on efficacy and safety of DOACs starting time within two weeks from AIS onset in patients undergoing systemic thrombolysis and/or mechanical thrombectomy. Results: Three studies were selected, overall including one hundred and six patients (62 females, 58.4%). Median National Institute of Health Stroke Scale (NIHSS) score at hospital admission ranged from 9 to 13 points. Median DOACs starting time ranged from 2 to 6 days. Median CHA Conclusion: Small sample size real life studies seem to demonstrate that the introduction of DOACs in the early phase of NVAF-related AIS undergoing urgent reperfusion is efficacious and safe. Prospective RCTs are necessary to confirm these findings.
Language	English
Publishing date	2019-02-24
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2588263-6
ISSN	2090-1860 ; 2090-1852
ISSN (online)	2090-1860
ISSN	2090-1852
DOI	10.1155/2019/9657073
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Clinical and Personal Predictors of Helmet-CPAP Use and Failure in Patients Firstly Admitted to Regular Medical Wards with COVID-19-Related Acute Respiratory Distress Syndrome (hCPAP-f Study).

Biomedicines

2023 Volume 11, Issue 1

Abstract: Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19 is substantially different from ARDS caused by other diseases and its treatment is dissimilar and challenging. As many studies showed conflicting results regarding the use of Non-invasive ... ...

Abstract	Acute Respiratory Distress Syndrome (ARDS) caused by COVID-19 is substantially different from ARDS caused by other diseases and its treatment is dissimilar and challenging. As many studies showed conflicting results regarding the use of Non-invasive ventilation in COVID-19-associated ARDS, no unquestionable indications by operational guidelines were reported. The aim of this study was to estimate the use and success rate of Helmet (h) Continuous Positive Airway Pressure (CPAP) in COVID-19-associated ARDS in medical regular wards patients and describe the predictive risk factors for its use and failure. In our monocentric retrospective observational study, we included patients admitted for COVID-19 in medical regular wards. hCPAP was delivered when supplemental conventional or high-flow nasal oxygen failed to achieve respiratory targets. The primary outcomes were hCPAP use and failure rate (including the need to use Bilevel (BL) PAP or oro-tracheal intubation (OTI) and death during ventilation). The secondary outcome was the rate of in-hospital death and OTI. We computed a score derived from the factors independently associated with hCPAP failure. Out of 701 patients admitted with COVID-19 symptoms, 295 were diagnosed with ARDS caused by COVID-19 and treated with hCPAP. Factors associated with the need for hCPAP use were the PaO2/FiO2 ratio < 270, IL-6 serum levels over 46 pg/mL, AST > 33 U/L, and LDH > 570 U/L; age > 78 years and neuropsychiatric conditions were associated with lower use of hCPAP. Failure of hCPAP occurred in 125 patients and was associated with male sex, polypharmacotherapy (at least three medications), platelet count < 180 × 109/L, and PaO2/FiO2 ratio < 240. The computed hCPAP-f Score, ranging from 0 to 11.5 points, had an AUC of 0.74 in predicting hCPAP failure (significantly superior to Call Score), and 0.73 for the secondary outcome (non-inferior to IL-6 serum levels). In conclusion, hCPAP was widely used in patients with COVID-19 symptoms admitted to medical regular wards and developing ARDS, with a low OTI rate. A score computed combining male sex, multi-pharmacotherapy, low platelet count, and low PaO2/FiO2 was able to predict hCPAP failure in hospitalized patients with ARDS caused by COVID-19.
Language	English
Publishing date	2023-01-13
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2720867-9
ISSN	2227-9059
ISSN	2227-9059
DOI	10.3390/biomedicines11010207
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Predictive ability of the new 2014 ESC prognostic model in acute pulmonary embolism.

Masotti, Luca / Panigada, Grazia / Landini, Giancarlo / Pieralli, Filippo / Corradi, Francesco / Lenti, Salvatore / Migliacci, Rino

International journal of cardiology

2016 Volume 202, Page(s) 801–803

MeSH term(s)	Acute Disease ; Biomarkers/analysis ; Cardiology ; Echocardiography ; Europe/epidemiology ; Hemodynamics/physiology ; Humans ; Incidence ; Predictive Value of Tests ; Prognosis ; Pulmonary Embolism/diagnosis ; Pulmonary Embolism/epidemiology ; Pulmonary Embolism/physiopathology ; Societies, Medical ; Survival Rate/trends
Chemical Substances	Biomarkers
Language	English
Publishing date	2016-01-01
Publishing country	Netherlands
Document type	Letter
ZDB-ID	779519-1
ISSN	1874-1754 ; 0167-5273
ISSN (online)	1874-1754
ISSN	0167-5273
DOI	10.1016/j.ijcard.2015.10.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1673: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: focus on real life studies.

Masotti, Luca / Grifoni, Elisa / Dei, Alessandro / Vannucchi, Vieri / Moroni, Federico / Panigada, Grazia / Spolveri, Stefano / Landini, Giancarlo

Journal of thrombosis and thrombolysis

2018 Volume 47, Issue 2, Page(s) 292–300

Abstract: Strong evidence for the use of direct oral anticoagulants (DOACs) in the early phase of non valvular atrial fibrillation (NVAF)-related acute ischemic stroke (AIS) is lacking, because this kind of patients were excluded from phase III randomized clinical ...

Abstract	Strong evidence for the use of direct oral anticoagulants (DOACs) in the early phase of non valvular atrial fibrillation (NVAF)-related acute ischemic stroke (AIS) is lacking, because this kind of patients were excluded from phase III randomized clinical trials (RCT) and ad hoc RCTs are ongoing. In the latest years a lot of real life studies on this topic have been published. The aim of our review was to focus on these. We reviewed the PubMed databases searching articles reporting on DOACs starting time within 2 weeks from AIS onset. We selected fifteen studies, eight with retrospective, six with prospective observational and one with a prospective, open-label, single arm design. Overall, 2920 patients (47.8% females) were included. In twelve studies median or mean age of patients was over 75 years. Mean or median NIHSS ad hospital admission was ≤ 12 in all studies. About one-third of patients (32.4%) received urgent reperfusion by systemic thrombolysis or mechanical thrombectomy. About one-fifth of patients (22.8%) had large infarct size. Median starting time of DOACs was reported in thirteen studies and it ranged from 2 to 8 days. About one-half of patients (45.9%) received a low dose of DOACs. In studies reporting on median or mean CHA
MeSH term(s)	Administration, Oral ; Aged ; Aged, 80 and over ; Anticoagulants/administration & dosage ; Anticoagulants/adverse effects ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/mortality ; Brain Ischemia/diagnosis ; Brain Ischemia/drug therapy ; Brain Ischemia/mortality ; Drug Administration Schedule ; Female ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Humans ; Ischemic Attack, Transient/diagnosis ; Ischemic Attack, Transient/drug therapy ; Ischemic Attack, Transient/mortality ; Male ; Middle Aged ; Recurrence ; Risk Factors ; Secondary Prevention/methods ; Stroke/diagnosis ; Stroke/drug therapy ; Stroke/mortality ; Time Factors ; Treatment Outcome
Chemical Substances	Anticoagulants
Language	English
Publishing date	2018-11-12
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	1230645-9
ISSN	1573-742X ; 0929-5305
ISSN (online)	1573-742X
ISSN	0929-5305
DOI	10.1007/s11239-018-1775-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4352: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Ninety-day prognosis of patients receiving direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: The real life evidence.

Masotti, Luca / Grifoni, Elisa / Dei, Alessandro / Vannucchi, Vieri / Moroni, Federico / Spolveri, Stefano / Panigada, Grazia / Landini, Giancarlo

Thrombosis research

2018 Volume 172, Page(s) 165–168

MeSH term(s)	Administration, Oral ; Aged ; Aged, 80 and over ; Anticoagulants/administration & dosage ; Anticoagulants/adverse effects ; Anticoagulants/therapeutic use ; Atrial Fibrillation/complications ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/drug therapy ; Brain Ischemia/complications ; Brain Ischemia/diagnosis ; Brain Ischemia/drug therapy ; Dabigatran/administration & dosage ; Dabigatran/adverse effects ; Dabigatran/therapeutic use ; Female ; Hemorrhage/chemically induced ; Humans ; Male ; Prognosis ; Pyrazoles/administration & dosage ; Pyrazoles/adverse effects ; Pyrazoles/therapeutic use ; Pyridines/administration & dosage ; Pyridines/adverse effects ; Pyridines/therapeutic use ; Pyridones/administration & dosage ; Pyridones/adverse effects ; Pyridones/therapeutic use ; Rivaroxaban/administration & dosage ; Rivaroxaban/adverse effects ; Rivaroxaban/therapeutic use ; Secondary Prevention ; Thiazoles/administration & dosage ; Thiazoles/adverse effects ; Thiazoles/therapeutic use
Chemical Substances	Anticoagulants ; Pyrazoles ; Pyridines ; Pyridones ; Thiazoles ; apixaban (3Z9Y7UWC1J) ; Rivaroxaban (9NDF7JZ4M3) ; Dabigatran (I0VM4M70GC) ; edoxaban (NDU3J18APO)
Language	English
Publishing date	2018-11-03
Publishing country	United States
Document type	Letter
ZDB-ID	121852-9
ISSN	1879-2472 ; 0049-3848
ISSN (online)	1879-2472
ISSN	0049-3848
DOI	10.1016/j.thromres.2018.11.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 863: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Early reduction of estimated Glomerular Filtration Rate (eGFR) predicts poor outcome in acutely ill hospitalized COVID-19 patients firstly admitted to medical regular wards (eGFR-COV19 study).

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

2022 Volume 153, Page(s) 113454

Abstract: Background: Analysis of autopsy tissues obtained from patients who died from COVID-19 showed kidney tropism for SARS-COV-2, with COVID-19-related renal dysfunction representing an overlooked problem even in patients lacking previous history of chronic ... ...

Abstract	Background: Analysis of autopsy tissues obtained from patients who died from COVID-19 showed kidney tropism for SARS-COV-2, with COVID-19-related renal dysfunction representing an overlooked problem even in patients lacking previous history of chronic kidney disease. This study aimed to corroborate in a substantial sample of consecutive acutely ill COVID-19 hospitalized patients the efficacy of estimated GFR (eGFR), assessed at hospital admission, to identify acute renal function derangement and the predictive role of its association with in-hospital death and need for mechanical ventilation and admission to intensive care unit (ICU). Methods: We retrospectively analyzed charts of 764 patients firstly admitted to regular medical wards (Division of Internal Medicine) for symptomatic COVID-19 between March 6th and May 30th, 2020 and between October 1st, 2020 and March 15th, 2021. eGFR values were calculated with the 2021 CKD-EPI formula and assessed at hospital admission and discharge. Baseline creatinine and GFR values were assessed by chart review of patients' medical records from hospital admittance data in the previous year. The primary outcome was in-hospital mortality, while ARDS development and need for non-invasive ventilation (NIV) and invasive mechanical ventilation (IMV) were the secondary outcomes. Results: SARS-COV-2 infection was diagnosed in 764 patients admitted with COVID-19 symptoms. A total of 682 patients (age range 23-100 years) were considered for statistical analysis, 310 needed mechanical ventilation and 137 died. An eGFR value <60 mL/min/1.73 m Conclusions: eGFR calculated at hospital admission correlated well with COVID-19-related kidney injury and eGFR values < 60 mL/min/1,73 m
MeSH term(s)	Acute Kidney Injury/diagnosis ; Acute Kidney Injury/therapy ; Adult ; Aged ; Aged, 80 and over ; COVID-19/therapy ; Glomerular Filtration Rate ; Hospital Mortality ; Hospitals ; Humans ; Middle Aged ; Respiratory Distress Syndrome ; Retrospective Studies ; Risk Factors ; SARS-CoV-2 ; Young Adult
Language	English
Publishing date	2022-07-21
Publishing country	France
Document type	Journal Article
ZDB-ID	392415-4
ISSN	1950-6007 ; 0753-3322 ; 0300-0893
ISSN (online)	1950-6007
ISSN	0753-3322 ; 0300-0893
DOI	10.1016/j.biopha.2022.113454
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.198: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report.

Masotti, Luca / Lorenzini, Gianni / Seravalle, Cristiana / Panigada, Grazia / Landini, Giancarlo / Cappelli, Roberto / Schulman, Sam

Journal of thrombosis and thrombolysis

2014 Volume 39, Issue 4, Page(s) 427–433

Abstract: Although new oral anticoagulants (NOAs) have been marketed in many countries, concern exists about the management of bleedings related to these drugs due to the lack of specific antidotes. The aim of our study was to report on real life management of ... ...

Abstract	Although new oral anticoagulants (NOAs) have been marketed in many countries, concern exists about the management of bleedings related to these drugs due to the lack of specific antidotes. The aim of our study was to report on real life management of NOAs-related life-threatening or major bleedings. We report data from consecutive cases of NOAs related major bleedings admitted to 4 hospitals since NOAs became marketed in Italy. We treated 8 patients, 4 males, with mean age 84 ± 7 years, 7 of whom were on dabigatran and one on rivaroxaban. The indication for NOA was atrial fibrillation. All bleedings were spontaneous and involving the gastro-intestinal tract. At the time of bleeding all patients had a drop in hemoglobin levels over 20 g/L. Creatinine clearance was ≤30 mL/min in 4 patients. All patients received general supportive measures, 4 of 8 patients were transfused with packed red cells and one patient received platelet transfusion. Three patients were treated with tranexamic acid and one patient on dabigatran received 4-factor prothrombin complex concentrate (PCC) with bleeding cessation, although coagulation parameters were not corrected. The median time for normalization of coagulation parameters was 3 days (range 1-6 days). All patients were discharged alive and NOAs were discontinued. In NOAs related major gastro-intestinal bleeding general supportive measures seem to be effective for the majority of patients. Despite promoting bleeding cessation, 4-factor PCC does not reverse abnormal coagulation parameters.
MeSH term(s)	Administration, Oral ; Aged ; Aged, 80 and over ; Anticoagulants/administration & dosage ; Anticoagulants/adverse effects ; Antifibrinolytic Agents/administration & dosage ; Blood Coagulation Factors/administration & dosage ; Female ; Hemorrhage/blood ; Hemorrhage/chemically induced ; Hemorrhage/drug therapy ; Humans ; Italy ; Male ; Tranexamic Acid/administration & dosage
Chemical Substances	Anticoagulants ; Antifibrinolytic Agents ; Blood Coagulation Factors ; prothrombin complex concentrates (37224-63-8) ; Tranexamic Acid (6T84R30KC1)
Language	English
Publishing date	2014-07-22
Publishing country	Netherlands
Document type	Journal Article ; Multicenter Study
ZDB-ID	1230645-9
ISSN	1573-742X ; 0929-5305
ISSN (online)	1573-742X
ISSN	0929-5305
DOI	10.1007/s11239-014-1112-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4352: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: The predictive role of the Bova risk score in acute normotensive pulmonary embolism: A retrospective analysis on a real life cohort.

Masotti, Luca / Verdiani, Valerio / Cei, Marco / Cioppi, Adriano / Di Natale, Massimo / Panigada, Grazia / Landini, Giancarlo

Thrombosis research

2015 Volume 137, Page(s) 221–223

MeSH term(s)	Aged ; Blood Pressure Determination/statistics & numerical data ; Cohort Studies ; Electrocardiography/statistics & numerical data ; Female ; Humans ; Italy/epidemiology ; Male ; Proportional Hazards Models ; Pulmonary Embolism/blood ; Pulmonary Embolism/diagnosis ; Pulmonary Embolism/mortality ; Reproducibility of Results ; Retrospective Studies ; Risk Assessment/methods ; Sensitivity and Specificity ; Survival Analysis ; Troponin/blood ; Ventricular Dysfunction, Right/blood ; Ventricular Dysfunction, Right/diagnosis ; Ventricular Dysfunction, Right/mortality
Chemical Substances	Troponin
Language	English
Publishing date	2015-11-21
Publishing country	United States
Document type	Letter
ZDB-ID	121852-9
ISSN	1879-2472 ; 0049-3848
ISSN (online)	1879-2472
ISSN	0049-3848
DOI	10.1016/j.thromres.2015.11.021
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 863: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito